Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 14/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 11/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 11/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4174389 | 0.89 | CHRM3 (0.49) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4143023 | 0.87 | CHRM3 (0.48) | CHRM3CHRM2CHRM1MEN1ALDH1A1 | |
| SCHEMBL4189032 | 0.85 | CHRM2 (0.55) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4619261 | 0.82 | CHRM3 (0.46) | CHRM3CHRM2CHRM1MEN1ALDH1A1 | |
| SCHEMBL4177298 | 0.81 | CHRM3 (0.56) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4172969 | 0.79 | CHRM2 (0.43) | CHRM3CHRM2CHRM1MEN1MAPT | |
| SCHEMBL4177144 | 0.78 | CHRM2 (0.60) | CHRM3CHRM2CHRM1 | |
| SCHEMBL18423386 | 0.76 | ROCK2 (0.49) | MAPTKMT2ASIGMAR1 | |
| SCHEMBL18423389 | 0.76 | ROCK2 (0.49) | MAPTKMT2ASIGMAR1 | |
| SCHEMBL4189353 | 0.76 | CHRM3 (0.46) | CHRM3CHRM2CHRM1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137623-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-28 | — | — | US | claimed |
| EP-1968980-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2008-09-17 | — | — | EP | claimed |
| WO-2007110782-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-10-04 | — | — | WO | claimed |
| US-20090137623-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-28 | — | — | US | disclosed |
| EP-1968980-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007110782-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137623-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM5 | CHRM3 5/4885CHRM2 1/4885CHRM1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.